BioTheryX Gets $92M

San Diego-based BioTheryX, which is developing protein degradation technology for use in creating cancer medicines, has raised $92M in a Series E funding round, according to the company. The funding was led by Farallon Capital Management, and also included new investors Avidity Partners, Deep Track Capital, Janus Henderson Investors, Lumira Ventures, Point72, Rock Springs Capital, Surveyor Capital, Tekla Capital Management, Alexandria Venture Investors, along with existing investors. The company said the funds will go to advance multiple molecular glues, PHM-based PROTACs and monovalent degraders, including BTX-1188, toward clinical development. Robert Williamson is President and CEO of BioTheryX.